[Effects of troxipide on acute gastric lesions in rats].
Effects of troxipide on several acute gastric lesions in rats were investigated in comparison with those of cetraxate. Troxipide (100, 200, 300 mg/kg) and cetraxate (100, 300, 1,000 mg/kg), given orally, dose-dependently protected the gastric mucosa from damage due to ethanol. Aspirin- and 0.6 N HCl-induced gastric lesions were dose-dependently inhibited by troxipide (200, 300 mg/kg), but only significantly inhibited by cetraxate at high dose (1,000 mg/kg). Troxipide (100, 200, 300 mg/kg) dose-dependently prevented the formation of gastric lesions induced by water-immersion stress, whereas cetraxate (600, 1,000 mg/kg) also significantly prevented gastric lesions. That is, protective effects of troxipide were much more potent than those of cetraxate against aspirin-, 0.6 N HCl- and water-immersion stress-induced gastric lesions, whereas both were almost equal against ethanol-induced gastric lesions. In addition, cytoprotective effects of troxipide against ethanol-induced lesions were most remarkable at 10, 30, 60 min after administration (100, 300 mg/kg) and lasted for up to 240 min. These results suggested that troxipide might be useful for the treatment of acute gastric lesions in humans.
D000208:Acute Disease; D000818:Animals; D000897:Anti-Ulcer Agents; D001241:Aspirin / Q000037:antagonists & inhibitors; D000431:Ethanol / Q000037:antagonists & inhibitors; D005753:Gastric Mucosa / Q000187:drug effects*; D006851:Hydrochloric Acid / Q000037:antagonists & inhibitors; D007101:Immersion; D008297:Male; D010880:Piperidines / Q000627:therapeutic use*; D051381:Rats; D013272:Stomach Diseases / Q000139:chemically induced / Q000517:prevention & control*; D013312:Stress, Physiological / Q000188:drug therapy; D014148:Tranexamic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D000897:Anti-Ulcer Agents; D010880:Piperidines; D000431:Ethanol; C000665:cetraxate; D014148:Tranexamic Acid; D006851:Hydrochloric Acid; D001241:Aspirin; C028936:troxipide